{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013191","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.392459+00:00","generated_at":"2026-06-12T07:22:31.630767+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback","bullets":["Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.","Board authorized $50M accelerated share repurchase program; reaffirmed FY2023 guidance product revenue $565-580M, adjusted EBITDA $355-370M.","Xtampza ER revenue grew 24% YoY to $41.2M; Nucynta franchise revenue up 8% YoY to $47.3M; Belbuca prescriptions up 3.5% QoQ.","FDA approved Nucynta for children ages 6+; pediatric extension could extend exclusivity to Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013191","json":"https://secwatch.observer/filing/0001558370-23-013191.json","markdown":"https://secwatch.observer/filing/0001558370-23-013191.md","text":"https://secwatch.observer/filing/0001558370-23-013191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/coll-20230803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:22:31.630767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfcffe89aac67e90518b0ca8cd6282f175f4cfd1","claim":"COLLEGIUM PHARMACEUTICAL, INC reported quarter ended June 30, 2023 results: revenue $135.5 million, net income $13.0 million, EPS $0.34 GAAP earnings per share (diluted). Guidance reaffirmed.","evidence_excerpt":"of this Current Report on Form 8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year ​ – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – ​ – Q2’23 GAAP Net Income of $13.0 Million – ​ – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – ​ – Board of Directors has Authorized","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$135.5 million"},{"label":"Net income","value":"$13.0 million"},{"label":"EPS","value":"$0.34 GAAP earnings per share (diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}